1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Epiomic Epidemiology Series: Glaucoma Forecast in 10 Major Markets 2016-2026

Epiomic Epidemiology Series: Glaucoma Forecast in 10 Major Markets 2016-2026

  • March 2016
  • -
  • Black Swan Analysis Ltd132
  • -
  • 48 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Glaucoma in 10 Major Markets

Glaucoma is a term describing a group of eye disorders that result in optic nerve damage. Glaucoma is divided into two main types: open-angle or closed-angle glaucoma. The condition develops when excess aqueous humour is inadequately drained, causing pressure to build. This may damage the optic nerves and the nerve fibres from the retina. There is a progressive loss of retinal ganglion cells and their axons, and the condition can lead to severe sight impairment.

This report provides the current prevalent population for Glaucoma across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Glaucoma have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Glaucoma include:

• Diabetes Mellitus
• Hypertension
• Dyslipidaemia
• Myopia
• Cataracts
• Intraocular hypertension
• Alzheimer’s disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Glaucoma’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Glaucoma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Glaucoma’s prevalent population.
• Identify sub-populations within Glaucoma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Glaucoma patients.

Table Of Contents

Epiomic Epidemiology Series: Glaucoma Forecast in 10 Major Markets 2016-2026
Table of Contents
- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors and Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis and Clinical Course
- Key Co-morbid Conditions/ Features Associated with the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Glaucoma
- Features of Glaucoma Patients
o Type and Classification of Glaucoma
o Progressive Glaucoma Co-morbidities
o Non-Progressive Glaucoma Co-morbidities
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix


List of Tables

- Tests used for glaucoma diagnosis
- Prevalence of glaucoma, total (000s)
- Prevalence of glaucoma, males (000s)
- Prevalence of glaucoma, females (000s)
- Type of glaucoma in patients, total (000s)
- Severity of glaucoma in POAG patients, total (000s)
- BMI of POAG patients, total (000s)
- Progressive profile of POAG patients, total (000s)
- Type of eye involvement in glaucoma patients, total (000s)
- Prevalence of cataracts in progressive glaucoma patients, total (000s)
- Prevalence of myopia in progressive glaucoma patients, total (000s)
- Prevalence of hypertension in progressive glaucoma patients, total (000s)
- Prevalence of diabetes in progressive glaucoma patients, total (000s)
- Prevalence of cataracts in non-progressive glaucoma patients, total (000s)
- Prevalence of myopia in non-progressive glaucoma patients, total (000s)
- Prevalence of hypertension in non-progressive glaucoma patients, total (000s)
- Prevalence of diabetes in non-progressive glaucoma patients, total (000s)
- Abbreviations and Acronyms used in the report
- USA Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- USA Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- France Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- France Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- Germany Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- Germany Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- Italy Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- Italy Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- Spain Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- Spain Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- United Kingdom Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- United Kingdom Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- Brazil Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- Brazil Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- Japan Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- Japan Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- India Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- India Prevalence of Glaucoma by 5-yr age cohort, females (000s)
- China Prevalence of Glaucoma by 5-yr age cohort, males (000s)
- China Prevalence of Glaucoma by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.